Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isaglidole SCHEMBL30659750 | 1.00 | NISCH (0.72) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| Isaglidole SCHEMBL10627482 | 0.90 | NISCH (0.60) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| Isaglidole SCHEMBL10627495 | 0.90 | NISCH (0.60) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL8091334 | 0.84 | NISCH (1.00) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL11001474 | 0.84 | NISCH (0.72) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| Hydrochloric Acid SCHEMBL6513698 | 0.83 | NISCH (0.97) | NISCHADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL6054462 | 0.82 | NISCH (0.69) | NISCHADRA2AADRA2BADRA2C | |
| SCHEMBL11098729 | 0.79 | NISCH (0.65) | NISCHADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL10765153 | 0.78 | NISCH (0.51) | NISCHADRA2AADRA2BADRA2C | |
| SCHEMBL8674200 | 0.76 | CYP1A2 (0.70) | NISCHADRA2AADRA2BADRA2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-3787631-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | Emory University (US) | 2021-03-10 | — | — | EP | claimed |
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | EMORY UNIVERSITY | 2021-02-25 | — | — | US | claimed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | MERCK & CO., INC. | 2006-07-20 | — | — | US | claimed |
| US-20060148721-A1 | Combination therapy for the treatment of dyslipidemia | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | claimed |
| EP-1635813-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | Merck & Co. Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1635773-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-03-22 | — | — | EP | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | claimed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | claimed |
| US-20020013268-A1 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor | FRYBURG DAVID A (US) | 2002-01-31 | — | — | US | claimed |
| EP-1145717-A2 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| US-4777181-A | ANTIDIABETIC AGENTS | BEIERSDORF AG (DE) | 1988-10-11 | — | — | US | claimed |
| EP-0228640-A1 | Substituted 4-fluoro-isoindolines, method for their preparation and their use as well as compositions containing them | Beiersdorf Aktiengesellschaft (DE) | 1987-07-15 | — | — | EP | claimed |
| EP-0226199-A2 | Isoindole derivatives as medicaments | Beiersdorf Aktiengesellschaft (DE) | 1987-06-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052603-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | RORA, RORB, RORC | NISCH 3975/4885ADRA2A 1297/4885ADRA2B 1404/4885 |
| US-20060148721-A1 | Combination therapy for the treatment of dyslipidemia | LIPC, LIPA, LPL | NISCH 921/4885ADRA2A 2128/4885ADRA2B 2138/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | NISCH 3425/4885ADRA2A 4072/4885ADRA2B 4081/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | NISCH 4605/4885ADRA2A 2707/4885ADRA2B 3046/4885 |
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | FABP4, GPR119, HMGCR | NISCH 1914/4885ADRA2A 375/4885ADRA2B 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.